IN2012DN02485A - - Google Patents

Download PDF

Info

Publication number
IN2012DN02485A
IN2012DN02485A IN2485DEN2012A IN2012DN02485A IN 2012DN02485 A IN2012DN02485 A IN 2012DN02485A IN 2485DEN2012 A IN2485DEN2012 A IN 2485DEN2012A IN 2012DN02485 A IN2012DN02485 A IN 2012DN02485A
Authority
IN
India
Prior art keywords
rheumatoid arthritis
methods
therapeutic agents
identifying
diagnosing
Prior art date
Application number
Inventor
Jr Glynn Dennis
Flavius Martin
Michael J Townsend
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of IN2012DN02485A publication Critical patent/IN2012DN02485A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
    • C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/686—Polymerase chain reaction [PCR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Food Science & Technology (AREA)
  • Rheumatology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Rehabilitation Therapy (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)

Abstract

Methods of identifying, diagnosing, and prognosing rheumatoid arthritis are provided, as well as methods of treating rheumatoid arthritis. Also provided are methods for identifying effective rheumatoid arthritis therapeutic agents and predicting responsiveness to rheumatoid arthritis therapeutic agents.
IN2485DEN2012 2009-09-03 2010-09-02 IN2012DN02485A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27594809P 2009-09-03 2009-09-03
US25242409P 2009-10-16 2009-10-16
PCT/US2010/047734 WO2011028945A1 (en) 2009-09-03 2010-09-02 Methods for treating, diagnosing, and monitoring rheumatoid arthritis

Publications (1)

Publication Number Publication Date
IN2012DN02485A true IN2012DN02485A (en) 2015-08-28

Family

ID=43625246

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2485DEN2012 IN2012DN02485A (en) 2009-09-03 2010-09-02

Country Status (11)

Country Link
US (2) US8728730B2 (en)
EP (2) EP2473637B1 (en)
JP (3) JP5996429B2 (en)
KR (1) KR20120104517A (en)
CN (2) CN107385034B (en)
BR (1) BR112012004777A2 (en)
CA (1) CA2772929A1 (en)
IN (1) IN2012DN02485A (en)
MX (2) MX2012002766A (en)
RU (2) RU2539112C2 (en)
WO (1) WO2011028945A1 (en)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2380911T (en) * 2003-11-05 2018-07-04 Roche Glycart Ag Antigen binding molecules with increased fc receptor binding affinity and effector function
US8645166B2 (en) 2007-07-16 2014-02-04 Russell W. Bessette System and method for scoring illness complexity to predict healthcare cost
TW201014605A (en) * 2008-09-16 2010-04-16 Genentech Inc Methods for treating progressive multiple sclerosis
BR112012004777A2 (en) 2009-09-03 2019-09-24 Genentech Inc Methods to Treat Diagnose and Monitor Rheumatoid Arthritis
CA2787783A1 (en) 2010-01-20 2011-07-28 Tolerx, Inc. Anti-ilt5 antibodies and ilt5-binding antibody fragments
CA2787755A1 (en) 2010-01-20 2011-07-28 Tolerx, Inc. Immunoregulation by anti-ilt5 antibodies and ilt5-binding antibody fragments
JP2013520476A (en) 2010-02-26 2013-06-06 ノヴォ ノルディスク アー／エス Stable antibody-containing composition
MA34287B1 (en) 2010-05-06 2013-06-01 Novartis Ag COMPOSITIONS AND METHODS OF USING LOW DENSITY THERAPEUTIC MULTIVALENT ANTIBODIES OF LIPOPROTEIN 6-RELATED PROTEIN (LRP6)
WO2011138392A1 (en) 2010-05-06 2011-11-10 Novartis Ag Compositions and methods of use for therapeutic low density lipoprotein -related protein 6 (lrp6) antibodies
AU2011257219B2 (en) 2010-05-28 2014-12-04 Novo Nordisk A/S Stable multi-dose compositions comprising an antibody and a preservative
KR20200145867A (en) 2010-12-06 2020-12-30 시애틀 지네틱스, 인크. Humanized antibodies to liv-1 and use of same to treat cancer
JP5885926B2 (en) * 2011-01-28 2016-03-16 シスメックス株式会社 Method for evaluating the presence of rheumatoid arthritis and biomarker set used in the method
BR112013021725A2 (en) * 2011-02-28 2016-11-01 Genentech Inc biological markers and methods for predicting response to b-cell antagonists
EP3290442A1 (en) 2011-11-04 2018-03-07 Novartis AG Low density lipoprotein-related protein 6 (lrp6) half-life extender constructs
MX2014009490A (en) 2012-02-10 2014-08-29 Novo Nordisk As Methods related to treatment of inflammatory diseases and disorders.
WO2013135789A1 (en) * 2012-03-15 2013-09-19 Universiteit Hasselt Means and methods for the determination of the joint destruction progression rate in rheumatoid arthritis patients
WO2013164440A1 (en) 2012-05-03 2013-11-07 Novo Nordisk A/S Methods related to treatment of inflammatory diseases and disorders
WO2014028374A1 (en) * 2012-08-17 2014-02-20 Eli Lilly And Company Biomarkers predictive of rheumatoid arthritis or systemic lupus erythematosus response to anti-baff antibody therapy
US20150376701A1 (en) * 2013-01-31 2015-12-31 The University Of Birmingham Biomarkers of autoimmune and/or chronic diseases associated with joint inflammation
EP2813850A1 (en) * 2013-06-10 2014-12-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting rheumatoid arthritis treatment response
WO2014204274A1 (en) * 2013-06-21 2014-12-24 가톨릭대학교 산학협력단 Biomarker for rheumatoid arthritis diagnosis or activity evaluation
TWI725931B (en) 2013-06-24 2021-05-01 美商建南德克公司 Anti-fcrh5 antibodies
CN103399147B (en) * 2013-08-07 2015-06-17 苏州大学 Polygalacturonic acid novel application
KR101628035B1 (en) * 2013-09-13 2016-06-09 인제대학교 산학협력단 Method for screening therapeutic agents of ovarian cancer using VSIG4
CN103513040B (en) * 2013-10-16 2015-03-11 常晓天 Application of protein CD38 to preparation of rheumatoid arthritis diagnosing marker
EP2863231A1 (en) * 2013-10-17 2015-04-22 Institut D'Investigaciones Biomédiques August Pi i Sunyer Diagnostic method for detecting a GABA(A) related autoimmune disease and related subject-matter
CA2942384C (en) 2014-03-12 2024-01-23 Icahn School Of Medicine At Mount Sinai Method for identifying kidney allograft recipients at risk for chronic injury
RU2554755C1 (en) * 2014-05-26 2015-06-27 Федеральное бюджетное учреждение науки "Санкт-Петербургский научно-исследовательский институт эпидемиологии и микробиологии им. Пастера" (ФБУН НИИ эпидемиологии и микробиологии имени Пастера) Diagnostic technique for rheumatoid arthritis
CN113444783B (en) 2014-06-26 2024-04-09 西奈山伊坎医学院 Method for diagnosing sub-clinical and clinical acute rejection by analyzing predictive gene set
KR20160048442A (en) * 2014-10-24 2016-05-04 가톨릭대학교 산학협력단 Biomarkers related to rheumatoid arthritis
ES2736948T3 (en) * 2015-01-29 2020-01-09 Ares Trading Sa Immunoassays for highly positively charged proteins
CN105988009B (en) * 2015-02-28 2018-03-13 复旦大学附属华山医院 Purposes of the Netrin 4 in the preparation of detection stomach cancer and prognostic marker is prepared
US20180120329A1 (en) * 2015-03-25 2018-05-03 La Jolla Institute For Allergy And Immunology Cxcl13 as an indicator of germinal activity and immune response
CA2985637A1 (en) * 2015-05-12 2016-11-17 The General Hospital Corporation Autoantigens for diagnosis of rheumatoid arthritis
TWI731861B (en) 2015-06-16 2021-07-01 美商建南德克公司 HUMANIZED AND AFFINITY MATURED ANTIBODIES TO FcRH5 AND METHODS OF USE
CN105200159B (en) * 2015-11-06 2018-06-15 北京致成生物医学科技有限公司 Osteoarthritis diagnosis and treatment reagent and its application
GB201521357D0 (en) * 2015-12-03 2016-01-20 Univ Liverpool Methods for predicting response to anti-TNF therapy
MA45324A (en) 2016-03-15 2019-01-23 Seattle Genetics Inc POLYTHERAPY USING ADC-LIV1 AND CHEMOTHERAPEUTIC AGENT
US11644473B2 (en) * 2016-04-15 2023-05-09 Rowan University Serum biomarkers for predicting and evaluating response to TNF inhibitor therapy in rheumatoid arthritis patients
US20170321286A1 (en) 2016-05-05 2017-11-09 Exact Sciences Corporation Detection of lung neoplasia by amplification of rna sequences
US10908159B2 (en) 2016-06-07 2021-02-02 The General Hospital Corporation Identification of a T cell epitope of Prevotella copri that induces T cell responses in patients with Rheumatoid arthritis
RU2622597C1 (en) * 2016-07-05 2017-06-16 Федеральное государственное бюджетное образовательное учреждение высшего образования "Кубанский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО КубГМУ Минздрава России) Method for joint pain syndrome prediction for patients with signs of connective tissue dysplasia
GB201616557D0 (en) * 2016-09-29 2016-11-16 Secretary Of State For Health The Assay for distinguishing between sepsis and systemic inflammatory response syndrome
CN106526196B (en) * 2016-10-08 2018-08-10 北京大学人民医院 Applications of the SR-A as Diagnosis of Rheumatoid Arthritis marker and intervention target spot
KR102049987B1 (en) * 2016-11-09 2019-11-28 아이씨엠 주식회사 Nkx3.2 FRAGMENT AND PHARMACEUTICAL COMPOSITION COMPRISING SAME
JP2020503260A (en) 2016-11-15 2020-01-30 ジェネンテック， インコーポレイテッド Administration for treatment with anti-CD20 / anti-CD3 bispecific antibodies
KR102588627B1 (en) * 2017-03-08 2023-10-16 김성진 Composition for preparing extracellular matrix using MAST4 gene and method for preparing the same
WO2018164507A2 (en) * 2017-03-08 2018-09-13 주식회사 길로 Extracellular matrix-producing composition using mast4 gene and preparation method therefor
US11325969B2 (en) * 2017-08-29 2022-05-10 Veritas Therapeutics Inc. FGL2 antibodies and binding fragments thereof and uses thereof
US11069431B2 (en) * 2017-11-13 2021-07-20 The Multiple Myeloma Research Foundation, Inc. Integrated, molecular, omics, immunotherapy, metabolic, epigenetic, and clinical database
CN111630182A (en) * 2018-01-24 2020-09-04 基因泰克公司 Diagnostic and therapeutic methods for the treatment of rheumatoid arthritis (RA)
CN108359726B (en) * 2018-02-28 2020-09-04 固安博健生物技术有限公司 Application of CORO2B as molecular diagnosis and treatment marker
JP7496324B2 (en) 2018-03-16 2024-06-06 サイファー メディシン コーポレイション Method and system for predicting responsiveness to anti-TNF therapy - Patent Application 20070123333
NZ769129A (en) 2018-04-16 2025-05-30 Icahn School Med Mount Sinai Method and kits for prediction of acute rejection and renal allograft loss using pre-transplant transcriptomic signatures in recipient blood
US20190336585A1 (en) * 2018-05-03 2019-11-07 John Lawrence Mee Method for sustainable human cognitive enhancement
US20190359985A1 (en) * 2018-05-22 2019-11-28 John Lawrence Mee Adjustable method for sustainable human cognitive enhancement
CN109142729B (en) * 2018-06-14 2021-04-23 郑州大学第一附属医院 A kind of lung cancer marker anti-HMGB3 autoantibody and its application
CA3104440A1 (en) * 2018-06-21 2019-12-26 Astraveus Microfluidic device and method for processing particles
US20190390193A1 (en) * 2018-06-23 2019-12-26 John Lawrence Mee Reversible method for sustainable human cognitive enhancement
US10723191B1 (en) 2018-07-01 2020-07-28 Softwheel Ltd. In-wheel three-arm suspension for vehicles
CN110917351A (en) * 2018-09-20 2020-03-27 华中科技大学同济医学院附属同济医院 Use of MBD2 inhibitors in the prevention and treatment of fibrotic diseases
EP3866835B1 (en) * 2018-10-19 2024-01-03 The Regents Of The University Of Michigan Method for monitoring autoimmune disease
CN109207584A (en) * 2018-11-01 2019-01-15 固安博健生物技术有限公司 Application of the MARCO as the molecular marker of early diagnosis osteoarthritis
EP3921335A4 (en) * 2019-02-08 2023-02-08 The Regents Of The University Of California COMPOSITIONS AND METHODS USING LAYILIN
CN120535477A (en) 2019-04-29 2025-08-26 索伦特治疗有限责任公司 3-Amino-4H-benzo [ E ] [1,2,4] thiadiazine 1, 1-dioxide derivatives as MRGX2 inhibitors
JP7686571B2 (en) * 2019-05-08 2025-06-02 ヤンセン バイオテツク，インコーポレーテツド Materials and methods for modulating T cell-mediated immunity
CA3145237A1 (en) 2019-06-27 2020-12-30 Scipher Medicine Corporation Developing classifiers for stratifying patients
CN110456074B (en) * 2019-08-27 2022-06-03 广东菲鹏生物有限公司 Citrullinated peptides and their applications, detection reagents and kits for rheumatoid arthritis
CN110408590B (en) * 2019-09-06 2022-10-25 遵义医学院附属医院 Method for inducing differentiation of human mesenchymal stem cells into osteoblasts and application thereof
GB201914079D0 (en) * 2019-09-30 2019-11-13 Univ London Queen Mary Method of predicting requirement for biologic therapy
KR102596937B1 (en) * 2019-11-07 2023-11-03 가톨릭대학교 산학협력단 Biomarker for diagnosing pannus of rheumatoid arthritis and use thereof
CN111091909B (en) * 2019-11-26 2022-05-31 中国信息通信研究院 Medical image identification method and device
CN113122628B (en) * 2019-12-30 2023-08-11 广州医科大学附属第三医院（广州重症孕产妇救治中心、广州柔济医院） Application of CLEC5A gene as marker in diagnosis and treatment of endometrial cancer
MX2022008328A (en) * 2020-01-10 2022-08-08 Somalogic Operating Co Inc Methods of determining impaired glucose tolerance.
CN112114126B (en) * 2020-08-13 2023-03-24 川北医学院 Diagnostic marker for systemic lupus erythematosus and application thereof
EP4217508A1 (en) * 2020-09-22 2023-08-02 The Secretary Of State For Defence Apparatus, kits and methods for predicting the development of sepsis
UY39488A (en) 2020-10-28 2022-04-29 Janssen Biotech Inc COMPOSITIONS AND METHODS FOR MODULATING DELTA GAMMA CHAIN-MEDIATED IMMUNITY
WO2022098638A2 (en) 2020-11-04 2022-05-12 Genentech, Inc. Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
CN112646887B (en) * 2020-12-23 2023-02-28 广州医科大学附属第五医院 ZNF239 as target for diagnosis and treatment of liver cancer
CN112946269B (en) * 2020-12-29 2022-12-27 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） Application of ABCA1 and CD68 as prognosis markers in preparation of liver cancer prognosis prediction kit
CN113186281B (en) * 2021-04-02 2023-02-28 广州医科大学附属第五医院 INAVA as a marker for hepatocellular carcinoma
CN113512582A (en) * 2021-04-15 2021-10-19 上海鸿准生物医药科技有限公司 Application of SLC22A18 in allergic and inflammatory diseases
CN113307835B (en) * 2021-04-21 2022-12-13 南通大学 siRNA and application thereof in preparation of chronic pain treatment medicine
KR20240005691A (en) 2021-04-30 2024-01-12 에프. 호프만-라 로슈 아게 Dosage for combination therapy with anti-CD20/anti-CD3 bispecific antibody and anti-CD79B antibody drug conjugate
WO2022241235A1 (en) 2021-05-14 2022-11-17 Genentech, Inc. Methods for treatment of cd20-positive proliferative disorder with mosunetuzumab and polatuzumab vedotin
EP4356136A4 (en) * 2021-06-13 2025-07-30 Technion Res & Dev Foundation Method for determining eligibility for anti-TNF-alpha therapy
EP4479973A1 (en) * 2022-02-16 2024-12-25 Ampel Biosolutions, LLC Unsupervised machine learning methods
CN114994327B (en) * 2022-04-12 2025-04-15 浙江大学医学院附属第二医院 Application of a biomarker GSDME
WO2024108154A2 (en) * 2022-11-18 2024-05-23 The United States Government As Represented By The Department Of Veterans Affairs Methods for treating rheumatoid arthritis using a syndecan-1 inhibitor or syntenin-1 inhibitor
CN116144761A (en) * 2023-02-24 2023-05-23 山西医科大学 Construction method and application of rheumatoid arthritis diagnosis classifier
CN116064784A (en) * 2023-03-23 2023-05-05 上海市光华中西医结合医院 Application of FGF10 in preparation of kit for detecting rheumatoid arthritis
JP2024179174A (en) * 2023-06-14 2024-12-26 シスメックス株式会社 Method for obtaining information regarding efficacy of chemotherapy for patients with membranous nephropathy, method for assisting in determining efficacy of chemotherapy for patients with membranous nephropathy, and reagent kit
CN117567626B (en) * 2024-01-15 2024-04-26 北京大学人民医院 An anti-citrullinated scavenger receptor A polypeptide antibody and its application in preparing a product for diagnosing rheumatoid arthritis
CN119424633B (en) * 2024-11-07 2025-07-25 浙江赛尔共银生物科技有限公司 Composition containing mesenchymal stem cells for treating degenerative arthritis and preparation method thereof

Family Cites Families (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4434227A (en) 1982-02-08 1984-02-28 Abbott Laboratories Immunoassay for class specific immunoglobulin antibodies
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
CA1261257A (en) 1984-09-19 1989-09-26 Helgi Valdimarsson Prognostic value of rheumatoid factor isotypes and their association with disease activity
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
WO1996033735A1 (en) 1995-04-27 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
DE69133566T2 (en) 1990-01-12 2007-12-06 Amgen Fremont Inc. Formation of xenogenic antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
DK0546073T3 (en) 1990-08-29 1998-02-02 Genpharm Int Production and use of transgenic, non-human animals capable of forming heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
JP4124480B2 (en) 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド Immunoglobulin variants
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5484892A (en) 1993-05-21 1996-01-16 Dana-Farber Cancer Institute, Inc. Monoclonal antibodies that block ligand binding to the CD22 receptor in mature B cells
US5595721A (en) 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
US6139832A (en) 1995-02-08 2000-10-31 Human Genome Sciences, Inc. Leukocyte adhesion inhibitor-1 (LAI-1) Polypeptides
AU1916795A (en) 1995-02-08 1996-08-27 Human Genome Sciences, Inc. Human chemokine beta-11 and human chemokine alpha-1
WO1996039522A1 (en) 1995-06-05 1996-12-12 Human Genome Sciences, Inc. Human chemokine beta-11 and human chemokine alpha-1
CA2219486A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
CA2249320C (en) 1996-03-20 2008-12-23 Immunomedics, Inc. Glycosylated humanized b-cell specific antibodies
PT939804E (en) 1996-10-25 2005-11-30 Human Genome Sciences Inc ALPHA NEUTROQUIN
PT1500329E (en) 1996-12-03 2012-06-18 Amgen Fremont Inc Human antibodies that specifically bind human tnf alpha
AU5705898A (en) 1996-12-17 1998-07-15 Schering Corporation Mammalian cell surface antigens; related reagents
US6183744B1 (en) 1997-03-24 2001-02-06 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
CA2232743A1 (en) 1997-04-02 1998-10-02 Smithkline Beecham Corporation A tnf homologue, tl5
IL134480A0 (en) 1997-09-12 2001-04-30 Apotech Sa Kay - an immune system protein and dna sequences encoding the same
US6461821B1 (en) * 1997-10-29 2002-10-08 Otsuka Pharmaceutical Co., Ltd. Smooth muscle growth inhibitory composition, diagnostic method for arteriosclerosis, and kit therefor
US6110695A (en) 1997-12-02 2000-08-29 The Regents Of The University Of California Modulating the interaction of the chemokine, B Lymphocyte Hemoattractant, and its Receptor, BLR1
AU2093499A (en) 1997-12-30 1999-07-19 Chiron Corporation Members of tnf and tnfr families
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
JP2002510481A (en) 1998-04-02 2002-04-09 ジェネンテック・インコーポレーテッド Antibody variants and fragments thereof
ES2204502T5 (en) 1999-01-07 2015-01-21 Zymogenetics, Inc. BR43x2 soluble receptor and methods of use in therapy
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
CN1237076C (en) 1999-01-15 2006-01-18 杰南技术公司 Polypeptide variants with altered effector function
DE05075555T1 (en) 1999-06-09 2007-02-08 Immunomedics, Inc. Immunotherapy of autoimmune diseases through the use of B cell-specific antibodies
BRPI0013391B8 (en) 1999-08-17 2021-05-25 Apotech R&D S A use of bcma polypeptides in the preparation of a pharmaceutical composition to treat an autoimmune disease or a b-cell lymphoproliferative disorder
DE10041402A1 (en) 2000-08-23 2002-03-14 Morphochem Ag Novel compounds that inhibit factor Xa activity
EP1218064B1 (en) * 1999-09-01 2005-06-01 Boehringer Ingelheim Pharmaceuticals Inc. COMPOSITIONS FOR TREATING AUTOIMMUNE DISEASEs CONTAINING A COMPOUND WHICH INHIBITS ICAM-LFA-1 INTERACTION AND A COMPOUND WHICH INHIBITS CD40-CD40 LIGAND INTERACTION
US7105149B1 (en) 1999-11-29 2006-09-12 The Trustees Of Columbia University In The City Of New York Isolation of five novel genes coding for new Fc receptors-type melanoma involved in the pathogenesis of lymphoma/myeloma
AU6155701A (en) 2000-05-12 2001-11-26 Amgen Inc Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci
AU2001268427B2 (en) 2000-06-16 2007-03-29 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to blys
US7118872B2 (en) 2000-08-18 2006-10-10 Dyax Corp. Binding polypeptides for B lymphocyte stimulator protein (BLyS)
UA83458C2 (en) 2000-09-18 2008-07-25 Байоджен Айдек Ма Інк. The isolated polypeptide baff-r (the receptor of the factor of activation of b-cells of the family tnf)
US20030092164A1 (en) 2000-11-07 2003-05-15 Gross Jane A. Human tumor necrosis factor receptor
US20030012783A1 (en) 2001-02-20 2003-01-16 Wayne Kindsvogel Antibodies that bind both BCMA and TACI
US6818406B2 (en) 2001-03-23 2004-11-16 Mayo Foundation For Medical Education And Research Rheumatoid arthritis markers
PT1385882E (en) 2001-05-11 2008-01-11 Amgen Inc Peptides and related molecules that bind to tall-1
US6905827B2 (en) 2001-06-08 2005-06-14 Expression Diagnostics, Inc. Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases
US7321026B2 (en) 2001-06-27 2008-01-22 Skytech Technology Limited Framework-patched immunoglobulins
EA007984B1 (en) 2001-08-03 2007-02-27 Дженентек, Инк. TACIs AND BR3 POLYPEPTIDES AND USE THEREOF
WO2003024991A2 (en) 2001-09-21 2003-03-27 Amgen Inc. Tall-1 receptor molecules and uses thereof
WO2003035846A2 (en) 2001-10-24 2003-05-01 National Jewish Medical And Research Center Structure of tall-1 and its cognate receptor
WO2003072827A1 (en) * 2001-10-31 2003-09-04 Children's Hospital Medical Center Method for diagnosis and treatment of rheumatoid arthritis
US20030224386A1 (en) * 2001-12-19 2003-12-04 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of rheumatoid arthritis
WO2003068821A2 (en) 2002-02-14 2003-08-21 Immunomedics, Inc. Anti-cd20 antibodies and fusion proteins thereof and methods of use
KR20040094705A (en) 2002-02-21 2004-11-10 듀크 유니버시티 Reagents and treatment methods for autoimmune diseases
GB0210121D0 (en) 2002-05-02 2002-06-12 Celltech R&D Ltd Biological products
DE60308196T2 (en) 2002-07-18 2007-08-02 Fabio Perini S.P.A. STORAGE UNIT FOR LONG PRODUCTS
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
ES2380621T3 (en) 2002-10-17 2012-05-16 Genmab A/S Human monoclonal antibodies against CD20
HU227217B1 (en) 2002-12-16 2010-11-29 Genentech Inc Immunoglobulin variants and uses thereof
US6962006B2 (en) 2002-12-19 2005-11-08 Acusphere, Inc. Methods and apparatus for making particles using spray dryer and in-line jet mill
SE0300959D0 (en) 2002-12-19 2003-04-02 Pharmacia Ab Methods for predicting therapeutic response to agents acting on the growth hormone receptor
US20050163775A1 (en) 2003-06-05 2005-07-28 Genentech, Inc. Combination therapy for B cell disorders
US20050095243A1 (en) 2003-06-05 2005-05-05 Genentech, Inc. Combination therapy for B cell disorders
IL156495A0 (en) * 2003-06-17 2004-01-04 Prochon Biotech Ltd Use of fgfr3 antagonists for treating t cell mediated diseases
JP4711963B2 (en) * 2003-09-15 2011-06-29 オクラホマ メディカル リサーチ ファウンデーション Methods using cytokine assays to diagnose, treat and evaluate inflammatory and autoimmune diseases
DE102004016437A1 (en) 2004-04-04 2005-10-20 Oligene Gmbh Method for detecting signatures in complex gene expression profiles
CA2501422C (en) 2004-04-29 2014-08-12 University Of Rochester Lymphoid chemokines in the diagnosis, monitoring and treatment of autoimmune disease
EP1765400A2 (en) 2004-06-04 2007-03-28 Genentech, Inc. Method for treating lupus
WO2006039238A2 (en) 2004-09-30 2006-04-13 The Goverment Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Irta2 antibodies and methods of use
WO2006041680A2 (en) 2004-10-05 2006-04-20 Genentech, Inc. Method for treating vasculitis
AU2006259583A1 (en) 2005-06-13 2006-12-28 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
BRPI0614183A2 (en) * 2005-07-25 2011-03-15 Trubion Pharmaceuticals Inc single-dose use of cd20-specific binding molecules
ZA200801354B (en) 2005-08-09 2009-08-26 Ares Trading Sa Methods for treating B-cell malignancies using TACI-lg fusion molecule
WO2007038754A2 (en) * 2005-09-27 2007-04-05 Source Mdx Gene expression profiling for identification monitoring and treatment of rheumatoid arthritis
WO2007038501A2 (en) 2005-09-27 2007-04-05 The Feinstein Institute For Medical Research Rheumatoid arthritis markers
EP2005279A2 (en) 2006-03-15 2008-12-24 Koninklijke Philips Electronics N.V. Remote control pointing technology with roll detection
GB0607774D0 (en) 2006-04-20 2006-05-31 Renovo Group Plc Medicaments
EP2021016B1 (en) 2006-04-21 2016-01-06 Janssen Biotech, Inc. Cxcl-13 antagonists and tnf-alpha antagonists for use in a combination therapy
EP2024514B1 (en) * 2006-05-16 2013-02-27 DxTerity Diagnostics Inc. Assessment of effect of an agent on a human biological condition using rodent gene expression panels
EP1857559A1 (en) 2006-05-16 2007-11-21 INSERM (Institut National de la Santé et de la Recherche Médicale) A method for predicting responsiveness to TNF alpha blocking agents
US20070269827A1 (en) * 2006-05-18 2007-11-22 Oklahoma Medical Research Foundation Predicting and Diagnosing Patients With Autoimmune Disease
WO2008156494A1 (en) * 2006-11-03 2008-12-24 The Johns Hopkins University Use of high-dose oxazaphosphorine drugs in combination with monoclonal antibodies for treating immune disorders
EP2084298A1 (en) 2006-11-09 2009-08-05 Institut National De La Sante Et De La Recherche Medicale Method for predicting therapeutic responsiveness to tnf-alpha blocking agents
US20080227704A1 (en) 2006-12-21 2008-09-18 Kamens Joanne S CXCL13 binding proteins
US20080199481A1 (en) 2007-02-21 2008-08-21 Astrazeneca Ab Compounds
WO2008104608A1 (en) 2007-03-01 2008-09-04 Universite Catholique De Louvain Method for the determination and the classification of rheumatic conditions
US20090136512A1 (en) 2007-03-30 2009-05-28 Peter Bugelski CXCL13 Antagonists and Their Use for the Treatment of Inflammatory Diseases
CN101711286A (en) * 2007-04-02 2010-05-19 健泰科生物技术公司 Biological markers predictive of rheumatoid arthritis response to b-cell antagonists
WO2008132176A2 (en) 2007-04-27 2008-11-06 Universite Catholique De Louvain Method for evaluating the response of an individual to tnf blocking therapy
KR20100037590A (en) 2007-06-08 2010-04-09 바이오겐 아이덱 엠에이 인코포레이티드 Biomarkers for predicting anti-tnf responsiveness or non-responsiveness
US20100261881A1 (en) 2007-09-03 2010-10-14 Protagen Ag Marker sequences for rheumatoid arthritis and use thereof
WO2009102366A2 (en) 2007-11-19 2009-08-20 Wyeth Expression of orphan gpr64 in inflammatory diseases
US8121883B2 (en) * 2008-02-07 2012-02-21 International Business Machines Corporation Method and system for automatically prioritizing opportunity based customer requirements
RU2587621C2 (en) 2009-04-01 2016-06-20 Дженентек, Инк. ANTI-FcRH5 ANTIBODIES, IMMUNOCONJUGATES THEREOF AND METHODS FOR USE THEREOF
BR112012004777A2 (en) 2009-09-03 2019-09-24 Genentech Inc Methods to Treat Diagnose and Monitor Rheumatoid Arthritis

Also Published As

Publication number Publication date
CN107385034B (en) 2021-08-17
JP6895718B2 (en) 2021-06-30
JP2017000141A (en) 2017-01-05
EP2473637A4 (en) 2013-05-01
RU2012112822A (en) 2013-10-10
US8728730B2 (en) 2014-05-20
MX353186B (en) 2018-01-05
CA2772929A1 (en) 2011-03-11
US20140341887A1 (en) 2014-11-20
JP5996429B2 (en) 2016-09-21
MX2012002766A (en) 2012-04-02
US20110052488A1 (en) 2011-03-03
CN102597268A (en) 2012-07-18
RU2014145058A (en) 2016-05-27
EP3211094A3 (en) 2017-11-01
BR112012004777A2 (en) 2019-09-24
EP3211094A2 (en) 2017-08-30
WO2011028945A1 (en) 2011-03-10
EP2473637A1 (en) 2012-07-11
CN107385034A (en) 2017-11-24
JP2021019594A (en) 2021-02-18
HK1245341A1 (en) 2018-08-24
KR20120104517A (en) 2012-09-21
EP2473637B1 (en) 2017-03-29
RU2539112C2 (en) 2015-01-10
JP2013503643A (en) 2013-02-04
US9822400B2 (en) 2017-11-21
CN102597268B (en) 2017-09-22

Similar Documents

Publication Publication Date Title
IN2012DN02485A (en)
PH12018500045A1 (en) Compositions and methods for treating and diagnosing asthma
MX353143B (en) Biological markers and methods for predicting response to b-cell antagonists.
WO2010036960A3 (en) Methods for treating, diagnosing, and monitoring lupus
EP3839068A3 (en) Methods for treating, diagnosing, and monitoring lupus
MY162933A (en) Chemical compounds
WO2013033627A3 (en) Diagnosis and treatment of arthritis using epigenetics
EA201291107A1 (en) METALLIC ENZYME INHIBITING COMPOUNDS
AU2011260390A8 (en) Means and methods for diagnosing pancreatic cancer in a subject
EA201491151A1 (en) METALLIC ENZYME INHIBITING COMPOUNDS
NZ606725A (en) Methods for predicting anti-cancer response
MX355543B (en) Peptidomimetic macrocycles.
EA201390704A1 (en) METALLIC ENZYME INHIBITING COMPOUNDS
TN2013000464A1 (en) Biomarkers for hedgehog inhibitor therapy
MX2010005395A (en) Method of treating arthritis.
WO2011088137A3 (en) Bad pathway gene signature
EP2516624A4 (en) CELL LINE 3M
MX337203B (en) Novel jnk inhibitor molecules.
BR112015013771A2 (en) predictive biomarker of response to treatment of nicotinic acetylcholine alpha 7 receptor activator
IN2012DN00852A (en)
MX357429B (en) Predictors for cancer treatment.
GB201312965D0 (en) Stem cell factor inhibitor
MX358726B (en) Predictive biomarker of survival in the treatment of renal cell carcinoma.
EA201390876A1 (en) METALLIC ENZYME INHIBITING COMPOUNDS
GB2510539A (en) Biomarkers of cancer